> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Trump Candidate for FDA Post Deletes His Tweets
- URL: https://www.fdaweb.com/trump-candidate-for-fda-post-deletes-his-tweets/
- Published: 2017-01-17T12:00:00.000Z
- Updated: 2026-09-14T22:00:23.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5137732

One of president-elect **Donald Trump**’s candidates ([see earlier story](https://www.fdaweb.com/trump-talks-to-2-silicon-valley-execs-about-fda-roles/)) for leading FDA has deleted his Twitter posts, presumably to block the public from learning his thoughts and criticisms about the agency and other areas. Entrepreneur **Balaji Srinivasan**, who founded a genomic testing company and works at the venture capital firm Andreessen Horowitz, met with Trump 1/12\. He is also aligned with billionaire tech investor **Peter Thiel** ([see earlier story](https://www.fdaweb.com/trump-team-looking-at-non-medical-person-to-lead-fda/)).

Having a technology background, Srinivasan should know that deleting his tweets does not necessarily make them vanish. Long after he “deleted” them, his critiques about FDA were still available on a Google cache, including this one, saying that America “can do vastly better than FDA w/ a Yelp for drugs, including MD star ratings (like all other products).” Those were apparently taken down 1/17, although their headers remained. To see more of Srinivasan’s archived posts, fully view this [post here](https://sciencebasedmedicine.org/donald-trump-vs-the-fda-be-afraid-be-very-afraid-of-the-loosening-of-drug-approval-standards/?ref=fdaweb.com) by Wayne State associate professor and surgical oncologist **David Gorski** at Science-based Medicine blog.

Meanwhile, Trump’s pick to lead HHS, House Budget Committee chair **Tom** **Price** (R-GA) ([see earlier story](https://www.fdaweb.com/trump-taps-rep-price-as-hhs-nominee/)), heads to a Senate Health, Education, Labor and Pensions Committee hearing 1/18\. Committee members are expected to grill Price on ethics concerns. Last week, he [agreed to divest](https://www.fdaweb.com/trumps-hhs-pick-will-divest-pharma-stock-ownership/) stock ownership in over 40 companies if his appointment is confirmed by the Senate. One potential divesture involves a tiny Australian biotech, Innate Immunotherapeutics, that offered Price and another congressman a sweetheart deal, according to a *Kaiser Health News* [report](http://www.thedailybeast.com/articles/2017/01/13/trump-s-hhs-nominee-tom-price-got-a-sweetheart-deal-on-health-stock.html?via=desktop&source=twitter). The company sold nearly $1 million in discounted shares to the lawmakers, who sit on House committees with the potential power to advance the company’s interests, the report says.